Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it’s not too late

References

• Jantunen E, Putkonen M, Nousiainen T, Pelliniemi TT, Mahlamaki E, Remes K. Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma. Bone Marrow Transplant 2003;31:347–351.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Kumar SK, Lacy MQ, et al. Comparison of high-doseCY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant 2009;43:619–625.
   PubMed Web of Science ®Google Scholar
• Mark T, Stern J, Furst JR, et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant 2008;14:795–798.
   PubMed Web of Science ®Google Scholar
• Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008;14:1045–1056.
   PubMed Web of Science ®Google Scholar
• Richman CM, Weiner RS, Yankee RA. Increase in circulating stem cells following chemotherapy in man. Blood 1976;47: 1031–1039.
   PubMed Web of Science ®Google Scholar
• Bensinger W, DiPersio JF, McCarty JM. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 2009;43:181–195.
   PubMed Web of Science ®Google Scholar
• Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD 3100, a CXCR4 antagonist. Blood 2003;102:2728–2730.
   PubMed Web of Science ®Google Scholar
• Liles WC, Rodger E, Broxmeyer HE, et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD 3100, a CXCR4 antagonist. Transfusion 2005;45:295–300.
   PubMed Web of Science ®Google Scholar
• De Clercq E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 2009;77:1655–1664.
   PubMed Web of Science ®Google Scholar
• Dugan MJ, Maziarz RT, Bensinger WI, et al. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin’s lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2010;45:39–47.
   PubMed Web of Science ®Google Scholar
• Basak GW, Urbanowska E, Boguradzki P, Torosian T, Halaburda K, Wiktor-Jedrzejczak W. Booster of plerixafor can be successfully used in addition to chemotherapy-based regimen to rescue stem cell mobilization failure. Ann Transplant 2010;15:61–67.
   PubMed Web of Science ®Google Scholar
• D’Addio A, Curti A, Worel N, et al. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2011;46:356–363.
   PubMed Web of Science ®Google Scholar
• Jantunen E, Kuittinen T, Mahlamaki E, Pyorala M, Mantymaa P, Nousiainen T. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience. Eur J Haematol 2011;86:299–304.
   PubMed Web of Science ®Google Scholar
• Hübel K, Fresen MM, Salwender H, et al. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone Marrow Transplant 2010 Oct 5. [Epub ahead of print]
   Google Scholar
• Basak GW, Knopinska-Posluszny W, Matuszak M, et al. Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience. Ann Hematol 2011;90:557–568.
   PubMed Web of Science ®Google Scholar
• Duarte RF, Shaw BE, Marin P, et al. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant 2011;46:52–58.
   PubMed Web of Science ®Google Scholar
• Burgstaler E. The negative effect of high peripheral white blood cell count on CD34+ cell recovery. J Clin Apheresis 2002;17:148.
   Google Scholar
• Burgstaler E, Winters J. Effects of high whole blood flow rates and high peripheral blood cell counts on CD34+ cell yield and cross-cellular contamination. Cytotherapy 2003;5:446.
   Google Scholar